Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023

Rhea-AI Summary

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) will release its fourth-quarter financial results for the period ending December 31, 2022, on March 7, 2023. The company will conduct a conference call at 4:30 p.m. Eastern Time on the same day, accessible via its Investor page. Marinus focuses on innovative therapeutics for seizure disorders, including its FDA-approved product ZTALMY® (ganaxolone) for CDKL5 deficiency disorder. This neuroactive steroid is also being studied in Phase 3 trials for tuberous sclerosis complex and refractory status epilepticus, aiming to enhance treatment options for both adults and pediatric patients.

Positive

• FDA approval of ZTALMY® for CDKL5 deficiency disorder expands market potential.
• Ongoing Phase 3 trials for ganaxolone in tuberous sclerosis complex and refractory status epilepticus could lead to additional revenue streams.

Negative

• None.

RADNOR, Pa.--(BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on March 7, 2023.

Participants may access the conference call via webcast on the Investor page of Marinus’ website at ir.marinuspharma.com/events-and-presentations. An archived version of the call will be available approximately two hours after the completion of the event on the website.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005156/en/

Company Contact

Sasha Damouni Ellis

Senior Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

sdamouni@marinuspharma.com

Source: Marinus Pharmaceuticals

FAQ

When will Marinus Pharmaceuticals announce its Q4 2022 financial results?

Marinus Pharmaceuticals will announce its Q4 2022 financial results on March 7, 2023.

What is ZTALMY® and what condition does it treat?

ZTALMY® (ganaxolone) is approved by the FDA for treating seizures associated with CDKL5 deficiency disorder.

At what time is the Marinus Pharmaceuticals conference call scheduled?

The conference call is scheduled for 4:30 p.m. Eastern Time on March 7, 2023.

What are the ongoing studies for ganaxolone?

Ganaxolone is currently being studied in Phase 3 trials for tuberous sclerosis complex and refractory status epilepticus.